Tag: Cancer: Cervical
More Women Aged ≥65 Years Have Late-Stage Cervical Cancer
Compared with women aged <65 years, those aged ≥65 have lower late-stage five-year relative survival
MRI-Guided Adaptive Brachytherapy Beneficial in Cervical Cancer
Only 81 of 1,318 patients had persistent disease at three months after treatment; 60 later achieved local control with no further treatment
Global Inequalities Remain in Cervical Cancer Incidence
Different patterns of age-specific incidence observed between countries with and without well-developed population-based screening and treatment
1.3 Million Older Women Still Receive Cervical Cancer Screening-Related Services
In 2019, Medicare fee-for-services spent $83.5 million on these potentially unnecessary services
Cervical Cancer Incidence Up Among Women Ages 30 to 34 Years
Findings similar across most races and cancer stages from 2012 to 2019
ASTRO: Sexual Function After Brachytherapy Less Often Assessed in Women
Sexual function less likely to be assessed in women versus men undergoing brachytherapy for genitourinary cancers
Black Women Have Increased Rates of Distant-Stage Cervical Cancer
However, White women in South aged 40 to 44 years have highest annual increase in distant-stage cervical cancer at rate of 4.5 percent
HPV Vaccination May Cut Risk for CIN2+ Recurrence
Effect estimate stronger for CIN2+ for disease related to HPV subtypes HPV 16 or HPV 18
Breast, Cervical Cancer Screening Decreased From 2018 to 2020
Prevalence of CRC screening remained stable with increase in stool testing offsetting decrease in colonoscopy
Sexual Minority Status Linked to Lower Odds of Pap Screen
Odds of ever undergoing pap testing lower for non-Hispanic White and Hispanic SM participants versus non-Hispanic White heterosexuals
